Skip to content

Asthma Health Center

Font Size

Omalizumab for Asthma - Topic Overview

Omalizumab (Xolair) is a medicine approved by the U.S. Food and Drug Administration (FDA) for use in people age 12 and older who have moderate or severe persistent asthma. It should be used only after first-line treatments (such as corticosteroids and long-acting beta2-agonists) have failed. Omalizumab is much more expensive than any of the conventional treatments for asthma. And its role in asthma treatment is not clear.

Omalizumab works by blocking immunoglobulin E (IgE) from attaching to allergens. When IgE attaches to an allergen, it sets off a process that eventually leads to the symptoms of an allergic reaction.

Recommended Related to Asthma

Managing Your Child's Asthma at School

If your child has been diagnosed with asthma, you know the difficulty of managing your child’s asthma symptoms at school. Many children with asthma have symptoms at school. That’s why it's important to get the school involved in managing your child’s asthma, so a responsible adult at the school knows when and how to administer asthma inhalers or other asthma treatment. Even if your child has mild asthma, working with the classroom teacher and other school officials is vital for managing your...

Read the Managing Your Child's Asthma at School article > >

Initial studies show that omalizumab reduces asthma episodes, improves peak expiratory flow (PEF), reduces the need for other medicines, and reduces emergency room visits and hospitalization.1 But it has been studied only in people with positive skin tests to indoor allergens such as dust mites, animal dander, cockroaches, and molds.

Omalizumab is injected, and the dose is determined by a person's body weight and IgE level.

Omalizumab appears to be effective in people who:1

  • Are age 12 and older.
  • Have moderate or severe persistent asthma.
  • Have asthma that can be improved.
  • Have had a positive skin or blood test for a specific allergen.
  • Have blood levels of immunoglobulin E between 30 and 700 IU per milliliter.

Omalizumab can be considered in people who meet the above criteria and whose asthma is not well controlled after using inhaled corticosteroids and long-acting beta2-agonists or leukotriene pathway modifiers for 3 months. People who use oral or injected (systemic) corticosteroids or who require high doses of inhaled corticosteroids for daily control can also consider using omalizumab.

Severe allergic reactions, including anaphylaxis, are possible when taking omalizumab, but this is rare. So people who get omalizumab are watched for 2 hours after they receive their first 2 doses. They should also carry epinephrine (EpiPen) in case they have an allergic reaction after omalizumab treatment.

    This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http:// cancer .gov or call 1-800-4-CANCER.

    WebMD Medical Reference from Healthwise

    Last Updated: February 22, 2013
    This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information.
    1
    Next Article:

    When Is Your Asthma Worse?

    When Is Your Asthma Worse?

    Take the WebMD Asthma assessment to get Personalized Action Plan

    Start Now

    Today on WebMD

    Lung and bronchial tube graphic
    5 common triggers.
    group jogging in park
    Should you avoid fitness activities?
     
    asthma inhaler
    Learn about your options.
    man feeling faint
    What’s the difference?
     
    Madison Wisconsin Capitol
    Slideshow
    woman wearing cpap mask
    Article
     
    red wine pouring into glass
    Slideshow
    Woman holding inhaler
    Quiz
     

    Pollen counts, treatment tips, and more.

    It's nothing to sneeze at.

    Loading ...

    Sending your email...

    This feature is temporarily unavailable. Please try again later.

    Thanks!

    Now check your email account on your mobile phone to download your new app.

    Man outdoors coughing
    Article
    Lung and bronchial tube graphic
    Article
     
    10 Worst Asthma Cities
    Slideshow
    runner
    Article
     

    WebMD Special Sections